In addition, targeting ESR2 with a selective agonist not interacting with ESR1 (ESR1 being responsible for many of the unwanted side effects, e.g., the growth stimulatory effects on the breast and uterus) may be an additional approach when considering the treatment of MCL, especially ibrutinib-resistant MCL. Here, ESR2 is linked to mantle cell lymphoma.